Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut. Published Online First: 10 August 2009. doi:10.1136/gut.2009.177089
Copyright © 2009 BMJ Publishing Group Ltd & British Society of Gastroenterology.

Paper

Screening For Colorectal Cancer; Randomised Trial Comparing Guaiac-Based And Immunochemical Faecal Occult Blood Testing And Flexible Sigmoidoscopy

Lieke Hol 1*, Monique E Van Leerdam 1, Marjolein Van Ballegooijen 1, Anneke J Van Vuuren 1, Herman Van Dekken 1, Jaqueline C.I.Y. Reijerink 2, Alexandra C M Van der Togt 3, Dik J F Habbema 1 and Ernst J Kuipers 1

1 Erasmus University Medical Center, Netherlands
2 Cancer Screening Organisation for Southwest Netherlands, Netherlands
3 Comprehensive Cancer Centre, Rotterdam, Netherlands

* To whom correspondence should be addressed. E-mail: l.hol.1{at}erasmusmc.nl.

Accepted 7 July 2009


Abstract

Background: Screening for colorectal cancer (CRC) is widely accepted, but there is no consensus on the preferred strategy. We conducted a randomised trial comparing participation and detection rates (DR) per screenee of guaiac-based faecal occult blood test (gFOBT), immunochemical FOBT (FIT), and flexible sigmoidoscopy (FS) for CRC screening.

Methods: A representative sample of the Dutch population (n=15.011), aged 50-74 years, was 1:1:1 randomised prior to invitation to one of the three screening strategies. Colonoscopy was indicated for screenees with a positive gFOBT or FIT, and for those in whom FS revealed a polyp with a diameter ≥10 mm; adenoma with ≥25% villous component or high grade dysplasia; serrated adenoma; ≥3 adenomas; ≥20 hyperplastic polyps; or CRC.

Results: The participation rate was 49.5% (95% confidence interval(CI) 48.1-50.9%) for gFOBT, 61.5% (CI:60.1-62.9%) for FIT and 32.4% (CI:31.1-33.7%) for FS screening. gFOBT was positive in 2.8%, FIT in 4.8% and FS in 10.2%. The DR of advanced neoplasia was significantly higher in the FIT (2.4%; OR 2.0; CI:1.3-3.1) and the FS arm (8.0%; OR 7.0; CI:4.6-10.7) than the gFOBT arm (1.1%). FS demonstrated a higher diagnostic yield of advanced neoplasia per 100 invitees (2.4; CI:2.0-2.8) than gFOBT (0.6; CI:0.4-0.8) or FIT (1.5; CI:1.2-1.9) screening.

Conclusion: This randomised population-based CRC-screening trial demonstrated superior participation and detection rates for FIT compared to gFOBT screening. FIT screening should therefore be strongly preferred over gFOBT screening. FS screening demonstrated a higher diagnostic yield per 100 invitees than both FOBTs.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs